The Column Group

Activity from announced rounds

Activity in this selectionUnited States · Oct 15, 2026 · Jul 18, 2026
Rounds participated in
1
Confirmed lead rounds
1
All roles disclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
$92.5M
1 disclosed · full round size, not this investor’s share

By stage

Series C+1

By primary sector

Biotech1

By country

United States1

Rounds

1 in this selection
Circle Pharma, Inc.

Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.

$92.5MSeries E
Lead